ES2139553T1 - Replicacion de virus de la gripe en un cultivo de celulas de mamiferos y produccion de vacuna. - Google Patents

Replicacion de virus de la gripe en un cultivo de celulas de mamiferos y produccion de vacuna.

Info

Publication number
ES2139553T1
ES2139553T1 ES97921094T ES97921094T ES2139553T1 ES 2139553 T1 ES2139553 T1 ES 2139553T1 ES 97921094 T ES97921094 T ES 97921094T ES 97921094 T ES97921094 T ES 97921094T ES 2139553 T1 ES2139553 T1 ES 2139553T1
Authority
ES
Spain
Prior art keywords
replication
cultivation
mammalian cells
influenza viruses
vaccine production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES97921094T
Other languages
English (en)
Inventor
Robert G Webster
Nicolai V Kaverin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Jude Childrens Research Hospital
Original Assignee
St Jude Childrens Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Research Hospital filed Critical St Jude Childrens Research Hospital
Publication of ES2139553T1 publication Critical patent/ES2139553T1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION PROPORCIONA LA REPLICACION DE LAS CEPAS DE MAS FUERTE CRECIMIENTO DEL VIRUS DE LA GRIPE, DERIVADAS DE AISLADOS CLINICOS, EN CELULAS CULTIVADAS DE MAMIFEROS, POR INFECCION DE LAS CELULAS DE MAMIFEROS CON LAS CEPAS DE FUERTE CRECIMIENTO, A FIN DE OBTENER CELULAS INFECTADAS, Y POR CULTIVO DE LAS CELULAS MIENTRAS SE MANTIENE EN EL MEDIO DE CULTIVO UN MARGEN DE CONCENTRACION DE TRIPSINA DE 0,05 A 1,0 MI G/ML, DONDE EL VIRUS REPLICADO RESULTANTE ES ADECUADO PARA SU USO EN VACUNAS CONTRA LA GRIPE DE LOS MAMIFEROS, ASI COMO PROCEDIMIENTOS DE VACUNACION QUE PROPORCIONA IGUALMENTE LA INVENCION.
ES97921094T 1996-04-05 1997-04-02 Replicacion de virus de la gripe en un cultivo de celulas de mamiferos y produccion de vacuna. Pending ES2139553T1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62838496A 1996-04-05 1996-04-05
US08/664,783 US5824536A (en) 1994-08-23 1996-06-17 Influenza virus replicated in mammalian cell culture and vaccine production

Publications (1)

Publication Number Publication Date
ES2139553T1 true ES2139553T1 (es) 2000-02-16

Family

ID=27090697

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97921094T Pending ES2139553T1 (es) 1996-04-05 1997-04-02 Replicacion de virus de la gripe en un cultivo de celulas de mamiferos y produccion de vacuna.

Country Status (8)

Country Link
US (2) US5824536A (es)
EP (1) EP0895535A4 (es)
AU (1) AU2722997A (es)
CA (1) CA2250716A1 (es)
DE (1) DE895535T1 (es)
ES (1) ES2139553T1 (es)
NO (1) NO984565L (es)
WO (1) WO1997038094A1 (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
CA2355270A1 (en) * 1998-12-17 2000-06-22 Aventis Pasteur Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
IL136232A0 (en) * 2000-05-18 2001-05-20 Bar Ilan University Res Author Measurements of enzymatic activity in a single, individual cell in population
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
EP2332651A3 (en) * 2001-10-25 2011-08-31 Bar Ilan University Interactive transparent individual cells biochip processor
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
US6830917B2 (en) 2001-12-10 2004-12-14 Baxter Healthcare S.A. Method of isolation and purification of trypsin from pronase protease and use thereof
AU2002239151A1 (en) * 2002-03-08 2003-09-22 Crucell Holland B.V. Use of recombinant trypsin for vaccine production
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
EP1499348B1 (en) 2002-04-26 2014-10-01 MedImmune, LLC Method for producing infectious influenza b virus in cell culture
US7262045B2 (en) 2003-02-25 2007-08-28 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
US20060110406A1 (en) * 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
IL154677A0 (en) * 2003-02-27 2003-09-17 Univ Bar Ilan A method and apparatus for manipulating an individual cell
RU2330885C2 (ru) * 2003-06-18 2008-08-10 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУ ГНЦ ВБ "Вектор" Роспотребнадзора) Способ получения живой культуральной вакцины против вируса гриппа
WO2004110484A1 (en) * 2003-06-18 2004-12-23 Gosudarstvenny Nauchny Tsentr Virusologii I Biotekhnologii 'vektor' Method for producing a live tissue-cultural vaccine against influenza virus
ATE478137T1 (de) * 2003-06-20 2010-09-15 Microbix Biosystems Inc Verbesserungen bei der virusproduktion
WO2004113492A1 (en) * 2003-06-26 2004-12-29 Molecular Cytomics Ltd. Improved materials for constructing cell-chips, cell-chip covers, cell-chip coats, processed cell-chips and uses thereof
US7888110B2 (en) 2003-06-26 2011-02-15 Seng Enterprises Ltd. Pico liter well holding device and method of making the same
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US8597597B2 (en) * 2003-06-26 2013-12-03 Seng Enterprises Ltd. Picoliter well holding device and method of making the same
WO2005008626A1 (en) * 2003-07-11 2005-01-27 University Of North Carolina At Chapel Hill Methods and systems for controlling a computer using a video image and for combining the video image with a computer desktop
US20050064524A1 (en) * 2003-08-11 2005-03-24 Mordechai Deutsch Population of cells utilizable for substance detection and methods and devices using same
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
AU2004308328B2 (en) 2003-12-23 2009-06-04 Medimmune, Llc Multi plasmid system for the production of influenza virus
BRPI0506610A (pt) * 2004-02-03 2007-05-02 Chemagis Ltd montelucaste sódico amorfo, processo de preparação de montelucaste sódico amorfo, composição farmacêutica, método de tratamento utilizando a administração de montelucaste sódico amorfo, co-precipitado amorfo de montelucaste sódico e processo de preparação de co-precipitado amorfo de montelucaste sódico
US7403647B2 (en) * 2004-09-13 2008-07-22 Seng Enterprises Ltd. Method for identifying an image of a well in an image of a well-bearing component
US20080063251A1 (en) * 2004-07-07 2008-03-13 Mordechai Deutsch Method and Device for Identifying an Image of a Well in an Image of a Well-Bearing
WO2006021959A2 (en) * 2004-08-25 2006-03-02 Seng Enterprises Ltd. Method and device for isolating cells
PT1789084E (pt) 2004-09-09 2011-02-22 Novartis Vaccines & Diagnostic Redução de riscos iatrogénicos pontenciais associados às vacinas contra a gripe
FR2878860A1 (fr) * 2004-12-08 2006-06-09 Vivalis Sa Lignees de cellules souches humaines derivees de cellules es et utilisations pour la production de vaccins et de proteines recombinantes
DK2368975T3 (en) * 2004-12-23 2015-01-05 Medimmune Llc Non-tumorigenic MDCK cell line for the propagation of viruses
DE602005023534D1 (de) * 2005-01-25 2010-10-21 Seng Entpr Ltd Mikrofluidische vorrichtung zur untersuchung zellen
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US20060286591A1 (en) 2005-06-21 2006-12-21 Medimmune Vaccines, Inc. Methods and compositions for expressing negative-sense viral RNA in canine cells
US7790434B2 (en) * 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
DE102005034043B4 (de) * 2005-07-18 2019-12-12 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Gemisch, enthaltend L-Carnitin und Trehalulose, sowie Produkt enthaltend das Gemisch
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
US20070141555A1 (en) * 2005-10-11 2007-06-21 Mordechai Deutsch Current damper for the study of cells
WO2007052163A2 (en) * 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
WO2007052245A1 (en) * 2005-11-03 2007-05-10 Seng Enterprises Ltd. Method and device for studying floating, living cells
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PL2368572T3 (pl) 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
US20090220541A1 (en) * 2005-11-04 2009-09-03 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant for adjuvanting split influenza vaccines
JP5491173B2 (ja) 2006-04-19 2014-05-14 メディミューン，エルエルシー イヌ細胞中でマイナス鎖ウイルスｒｎａを発現させるための方法および組成物
EP3456348B1 (en) 2006-09-11 2025-03-26 Seqirus UK Limited Making influenza virus vaccines without using eggs
KR101464783B1 (ko) 2006-09-15 2014-11-26 메디뮨 엘엘씨 높은 역가로 바이러스 증식을 지원하는 ｍｄｃｋ 세포주 및 이를 이용한 생물반응기 공정
WO2008036285A1 (en) * 2006-09-18 2008-03-27 Energex Systems, Inc. Method of treating viral infections with ultraviolet light
EP1911836A1 (en) 2006-10-12 2008-04-16 AVIR Green Hills Biotechnology Trading GmbH Medium supplement for virus production
US20110053248A1 (en) * 2006-10-23 2011-03-03 Medimmune, Llc Serum-Free Virus Propagation Platform For A Virus Vaccine Candidate
PL2121011T3 (pl) * 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
WO2008076371A2 (en) * 2006-12-15 2008-06-26 Schering-Plough Ltd. Method for replicating influenza virus in culture
UA100849C2 (ru) * 2006-12-15 2013-02-11 Шеринг-Плау Лтд. Способ репликации вируса гриппа в культуре
US20090060889A1 (en) * 2007-03-12 2009-03-05 Von Hofe Eric Ii-RNAi involved Ii suppression in cancer immunotherapy
TW200911274A (en) * 2007-04-13 2009-03-16 Academia Sinica Alpha-galatosyl ceramide analogs and their use as immunotherapies
US7758867B2 (en) * 2007-06-15 2010-07-20 Biotrion Co., Ltd. Attenuated influenza virus and a live vaccine comprising the same
EP2674486A1 (en) 2007-06-18 2013-12-18 MedImmune, LLC Influenza B viruses having alterations in the hemaglutinin polypeptide
US9145540B1 (en) 2007-11-15 2015-09-29 Seng Enterprises Ltd. Device for the study of living cells
US9975118B2 (en) 2007-11-15 2018-05-22 Seng Enterprises Ltd. Device for the study of living cells
RU2377295C1 (ru) * 2008-06-11 2009-12-27 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) Питательная среда для культивирования клеток млекопитающих
US7928077B2 (en) * 2008-07-11 2011-04-19 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies
KR101707569B1 (ko) * 2008-08-01 2017-02-16 감마 백신즈 피티와이 리미티드 인플루엔자 백신
KR20110074563A (ko) 2008-09-24 2011-06-30 메디뮨 엘엘씨 바이러스의 정제 방법
KR20110074564A (ko) 2008-09-24 2011-06-30 메디뮨 엘엘씨 세포 배양, 바이러스 증식 및 바이러스 정제를 위한 방법
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
EP2427547A1 (en) * 2009-05-08 2012-03-14 GlaxoSmithKline Biologicals S.A. Method for producing virus from cell culture involving homogenization
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
EP2295543A1 (en) * 2009-09-11 2011-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the preparation of an influenza virus
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
TW201202425A (en) 2010-04-28 2012-01-16 Abbott Biologicals Bv Production of viral components
CA2796213A1 (en) * 2010-05-06 2011-11-10 Novartis Ag Organic peroxide compounds for microorganism inactivation
CN103096922B (zh) 2010-07-06 2019-08-06 变异生物技术公司 用于治疗流行性感冒的组合物和方法
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
US20130323280A1 (en) 2011-01-13 2013-12-05 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US20140079732A1 (en) 2011-01-27 2014-03-20 Gamma Vaccines Pty Limited Combination vaccines
WO2012122625A1 (en) 2011-03-14 2012-09-20 National Research Council Of Canada Method of viral production in cells
WO2012151391A2 (en) 2011-05-04 2012-11-08 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
SG11202005528PA (en) 2018-01-18 2020-07-29 Yisheng Biopharma Singapore Pte Ltd Method for adapting influenza viruses to vero cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2445301A (en) * 1941-12-05 1948-07-13 Univ Pennsylvania Influenza vaccine
BE662899A (es) * 1964-04-22
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
ATE542891T1 (de) * 1994-11-10 2012-02-15 Baxter Healthcare Sa Verfahren zur herstellung von biologischen produkten in protein-freier kultur
AU694592B2 (en) * 1994-11-16 1998-07-23 St. Jude Children's Research Hospital Novel replication process

Also Published As

Publication number Publication date
CA2250716A1 (en) 1997-10-16
US5824536A (en) 1998-10-20
AU2722997A (en) 1997-10-29
EP0895535A1 (en) 1999-02-10
EP0895535A4 (en) 2004-09-15
US6344354B1 (en) 2002-02-05
NO984565L (no) 1998-12-03
WO1997038094A1 (en) 1997-10-16
DE895535T1 (de) 2000-03-02
NO984565D0 (no) 1998-09-30

Similar Documents

Publication Publication Date Title
DE10144906B4 (de) Verfahren zur großtechnischen Herstellung von Impfstoffen
ES2129386T1 (es) Vacuna contra influenza.
MX9306841A (es) Vacuna a base de ureasa contra la infeccion por helicobacter en mamiferos.
BRPI0407636A (pt) meio de cultura de células, linhagem de células animais, métodos para produzir um meio de cultura condicionado, células animais, uma cultura de células animais, vìrus em uma cultura de células animais, ou, de preferência, humanas diplóides dependentes de ancoragem, método para produzir uma vacina, e, população de vìrus
LU91381I2 (fr) OPTAFLU-Définition du produit: Vaccin grippal préparé à partir du virus de la grippe dans une culture celluluaire ou les cellules sont cultivées à unetempérature comprise entre 30°C et 36°C pour la r éplication des virus
EA200900784A1 (ru) Вакцины, включающие антиген из четырех штаммов вируса гриппа
US4188375A (en) Process for the preparation of vaccines
EA200200604A1 (ru) Производство вакцин
EP1427817A1 (de) Vermehrung von viren in zellkultur
AR032575A1 (es) Uso de una preparacion antigenica de gripe para la fabricacion de una vacuna intradermica de la gripe y estuche farmaceutico que comprende dicha vacuna
BR0212047A (pt) Uso de imunogene, poliaminoácido ou conjugado, composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra amilóide, e, linhagem de célula estável
CO5540349A2 (es) Preparacion vacunal de virus de influenza inactivado
ES2074968B1 (es) Nuevas cepas de pseudomonas aeruginosa atenuadas.
ES2042828T3 (es) Procedimiento de preparacion de vacunas contra tumores modificadas por virus para la inmunoterapia de metastasis de tumores.
MX9802285A (es) Vacunas y glicoproteinas de virus de parainfluenza.
ES2038689T3 (es) Procedimiento de cultivo del virus de la rinotraqueitis infecciosa de la pava, y vacuna preparada a partir del virus asi obtenido.
ES2175863T3 (es) Producto liofilizado que contiene beta-1,3-glucano procedente de euglena, su preparacion y utilizacion.
ES2106784T3 (es) Factor de transferencia y metodos de uso.
PE72699A1 (es) Antigeno del rotavirus, vacuna y agente diagnostico para infeccion por rotavirus y un metodo para producir el antigeno
DE3889138D1 (de) Influenza-Impfstoff.
CO4980849A1 (es) Composiciones farmaceuticas -2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona(la mivudina), y su uso en terapia medica
BR0102322A (pt) Vìrus de uma cepa de vìrus de doença bursal infecciosa, vacina contra doença bursal infecciosa, métodos para a preparação do vìrus, e da vacina, e, uso do vìrus
BR0307512A (pt) Métodos para produzir uma linhagem de células contìnua, para gerar e/ou isolar e/ou manter uma cepa de vìrus da doença de marek, para produzir um antìgeno diagnóstico de um vìrus da doença de marek, para preparar uma vacina capaz de induzir proteção contra doença em um vertebrado, e para proteger um vertebrado contra doença, célula ou sua prole, preparação de células, uso das mesmas, vacina, e, uso da mesma
AR042237A1 (es) Obtencion de estructuras cocleares, composiciones vacunales, adyuvantes y sus intermediarios
ES2085888T3 (es) Composicion de vacuna.